Global ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis Report [2022-30] I Insights10

Global ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

The global market for ADHD is estimated to be worth $29.56 Bn in 2022 and is projected to expand to $41.08 Bn by 2030, with a CAGR of 4.2% over the forecast period. According to statistics, the estimated total annual national healthcare expenses of ADHD in Europe was $356.14 Mn, while those in Asia were $53.16 Bn. The market segments by drug kinds, age groups, distribution methods, and type of psychotherapy are highlighted in the Insights10 report. Eli Lily and Co., Pfizer, Johnson & Johnson, and Lupin are the top companies controlling the global market.

ID: IN10GLPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Global

Buy Now

Global Attention Deficit Hyperactivity Disorder (ADHD) Market Executive Summary

Global Attention Deficit Hyperactivity Disorder (ADHD) market size is at around $29.56 Bn in 2022 and is projected to reach $41.08 Bn in 2030, exhibiting a CAGR of 4.2% during the forecast period. ADHD is a neurodevelopmental disorder that affects children and adults and is characterized by difficulty paying attention, impulsivity, and hyperactivity. The global ADHD market refers to the market for products and services related to the treatment of ADHD. The global ADHD market is expected to grow significantly in the coming years due to increasing awareness about the disorder, growing prevalence, and the availability of new treatments.

In North America, the estimated total yearly economic cost for people with ADHD (including children, adolescents, and adults) ranged from $2.27 Bn to $20.27 Bn. For the US and Canada, the estimated cost in GDP terms was 0.1% and 0.13%, respectively. According to statistics for the adult population, the projected total yearly national expenses of ADHD in Europe ranged from $356.14 Mn to $416.80 Mn. Estimated expenses were 0.1% for Denmark, 0.15% for France, 0.12% for the Netherlands, and 0.14% for the UK as a percentage of GDP. ADHD was projected to cost $53.16 Mn in Asia and $27.98 Mn in Australia for children and adolescents.

The market is driven by factors such as the increasing prevalence of ADHD, rising awareness about the disorder, and the availability of new treatments. The increasing use of stimulant medications such as Ritalin and Adderall is also driving the market. However, the high cost of treatment, the limited effectiveness of existing therapies, and the lack of access to care in developing countries are some of the factors that could potentially hinder the growth of the market.

Global Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis

Market Dynamics

Market Growth Drivers

There are several factors that may be driving the market for ADHD Market in a Global context. Some of them include-

The global burden of ADHD is on the rise - ADHD is a common neurodevelopmental disorder that affects children and adults worldwide. It is estimated that ADHD affects around 5% of children and 2.5% of adults globally. ADHD is more common in males than females and is often first diagnosed in childhood. The early onset of ADHD results in productivity loss in young adults and causes an economic burden.
Developed Countries’ piqued interest in therapeutics development- ADHD economic impact reveals total costs ranged from $356 Mn to $20.27 Bn for national estimates and from $831.38 - $20,538 per person. For per-person estimates based on marginal costs, the range was between $244.15 and $18,751, and for national estimates, it was between $12.18 Mn and $141.33 Bn in the study conducted among high-income countries of North America and Europe.
New advancements in technologies that deliver non-pharmaceutical therapeutics such as video games aim to target ADHD management.

Market Restraints

The diagnosis of ADHD is sensitive to the expertise of specialists and usually presents as cases of mental health disorders. Adult-stage diagnosis of ADHD also is a common phenomenon, but due to a lack of proper documentation and access to specialists, may defer or prevent timely diagnosis. The cost of ADHD treatment can be a barrier for some people, as these treatments can be expensive and may not be covered by insurance in all cases. The availability of generic drugs and over-the-counter alternatives, free availability of Adderall substitutes pose a challenge for formal therapeutics that are prescribed on regulated by the medical authorities. The competing treatment alternatives are not evaluated for clinical effectiveness with other alternatives in a documented manner, which deters viable comparison. In some cases, people may not be aware that they have ADHD, or they may not be aware of the treatment options that are available to them. This can limit the market for ADHD treatments.

Competitive Landscape

Key Players

Eli Lily and Co.
Pfizer
Johnson & Johnson
Lupin
Novartis
Takeda Pharmaceuticals

Notable Recent Updates

January 2023 - PureTech says ADHD treatment shows improved attentional functioning. The toplined results for the pivotal study of PureTech Health PLC's EndeavorRx medication have claimed "strong improvements in attention and broader clinical outcomes". The STARS-ADHD-Adolescents label expansion study's findings, according to the London-based biotherapeutics firm's created subsidiary Akili Inc., a digital medicine company, demonstrated improvement in attentional functioning after just 4 weeks of treatment. The EndeavorRx research examines the efficacy and safety of the treatment for attention deficit hyperactivity disorder in teenagers between the ages of 13 and 17 years old. EndeavorRx is the first US FDA-approved medication administered through a video game experience.

December 2022 - Through a deal involving a Special Purpose Acquisition Company (SPAC), Akili Interactive Labs went public. At the end of January, the agreement was announced. Akili's market value at the time of the agreement was $1 Bn. In August, Akili completed the transaction with Social Capital Suvretta Holdings Corp. I. By that time, the transaction had brought in $163 Mn. The Boston-based business developed EndeavorRx, a prescription video game, with the goal of enhancing attention function in kids with ADHD. The business received an FDA 510(k) clearance for the technology in 2021. The use of video game therapy for depressed adults has also been studied.

Healthcare Policies and Regulatory Landscape

The American Psychiatric Association (APA) publishes the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). The International Classification of Diseases (ICD-10) is a publication of the World Health Organization (WHO) that provides diagnostic criteria for ADHD. There may be regional differences in the precise standards and procedures used for the diagnosis and management of ADHD. The Food and Drug Administration (FDA) is in charge of approving medications in the US for the treatment of ADHD. The European Medicines Agency (EMA) of the EU is in charge of examining and approving medications for usage there. Drugs for the treatment of ADHD must have approval from Health Canada's Therapeutic Products Directorate (TPD). Medication regulation in Australia is handled by the Therapeutic Goods Administration (TGA). The Ministry of Health, Labour, and Welfare in Japan is in charge of approving medications for the treatment of ADHD.

Reimbursement Scenario

The availability and reimbursement of treatment for ADHD varies widely around the world. Some countries have robust systems in place for diagnosing and treating ADHD, and medications and other treatments may be widely available and covered by public or private insurance. In other countries, access to treatment may be more limited, and patients may need to pay for care out of pocket. In the US, treatment for ADHD is generally available and may be covered by public or private insurance. In the US, Medicaid, the government-funded healthcare program for low-income individuals and families, covers treatment for ADHD. In Canada, treatment for ADHD is generally available and may be covered by provincial or territorial healthcare plans. In Australia, treatment for ADHD is generally available and may be covered by the country's universal healthcare system, known as Medicare.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

By Geography

APAC ADHD (Attention Deficit Hyperactivity Disorder) Market

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Europe ADHD (Attention Deficit Hyperactivity Disorder) Market

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

North America ADHD (Attention Deficit Hyperactivity Disorder) Market

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Middle East ADHD (Attention Deficit Hyperactivity Disorder) Market

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Africa ADHD (Attention Deficit Hyperactivity Disorder) Market

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Latin America ADHD (Attention Deficit Hyperactivity Disorder) Market

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.